Lina M. Carmona Echeverria
YOU?
Author Swipe
View article: Combining tissue biomarkers with mpMRI to diagnose clinically significant prostate cancer. Analysis of 21 biomarkers in the PICTURE study
Combining tissue biomarkers with mpMRI to diagnose clinically significant prostate cancer. Analysis of 21 biomarkers in the PICTURE study Open
Background Serum PSA and digital rectal examination remain the key diagnostic tools for detecting prostate cancer. However, due to the limited specificity of serum PSA, the applicability of this marker continues to be controversial. Recent…
View article: Regional Histopathology and Prostate MRI Positivity: A Secondary Analysis of the PROMIS Trial
Regional Histopathology and Prostate MRI Positivity: A Secondary Analysis of the PROMIS Trial Open
Background The effects of regional histopathologic changes on prostate MRI scans have not been accurately quantified in men with an elevated prostate-specific antigen (PSA) level and no previous biopsy. Purpose To assess how Gleason grade,…
View article: 120P The compartment-specific spatial transcriptomic landscape of 3D cultured Gleason 7 prostate cancer
120P The compartment-specific spatial transcriptomic landscape of 3D cultured Gleason 7 prostate cancer Open
View article: 99P The transcriptional atlas of co-targeted PIM/PI3K/mTOR ex-vivo patient-derived prostate cancer as revealed by spatial transcriptomics
99P The transcriptional atlas of co-targeted PIM/PI3K/mTOR ex-vivo patient-derived prostate cancer as revealed by spatial transcriptomics Open
View article: Spatial transcriptomics analysis of co-targeted PIM and PI3 K/mTOR in multikinase inhibitor and single kinase inhibitor combination-treated patient-derived prostate cancer explants
Spatial transcriptomics analysis of co-targeted PIM and PI3 K/mTOR in multikinase inhibitor and single kinase inhibitor combination-treated patient-derived prostate cancer explants Open
View article: Exploring the Value of BRD9 as a Biomarker, Therapeutic Target and Co-Target in Prostate Cancer
Exploring the Value of BRD9 as a Biomarker, Therapeutic Target and Co-Target in Prostate Cancer Open
Background and aims: Despite recent advances in advanced prostate cancer treatments, clinical biomarkers or treatments for men with such cancers are imperfect. Targeted therapies have shown promise, but there remain fewer actionable target…
View article: BRD9 Expression, Alteration, Survival And Pathway Analysis In 11 Independent Prostate Cancer Cohorts
BRD9 Expression, Alteration, Survival And Pathway Analysis In 11 Independent Prostate Cancer Cohorts Open
Background and aims: Despite recent advances in advanced prostate cancer treatments, there are no clinically useful biomarkers or treatments for men with such cancers. Targeted therapies have shown promise, but there remain fewer actionabl…
View article: Evaluation of PSA and PSA Density in a Multiparametric Magnetic Resonance Imaging-Directed Diagnostic Pathway for Suspected Prostate Cancer: The INNOVATE Trial
Evaluation of PSA and PSA Density in a Multiparametric Magnetic Resonance Imaging-Directed Diagnostic Pathway for Suspected Prostate Cancer: The INNOVATE Trial Open
Objectives: To assess the clinical outcomes of mpMRI before biopsy and evaluate the space remaining for novel biomarkers. Methods: The INNOVATE study was set up to evaluate the validity of novel fluidic biomarkers in men with suspected pro…
View article: Author Correction: Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancer
Author Correction: Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancer Open
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
View article: A critical evaluation of visual proportion of Gleason 4 and maximum cancer core length quantified by histopathologists
A critical evaluation of visual proportion of Gleason 4 and maximum cancer core length quantified by histopathologists Open
View article: False Positive Multiparametric Magnetic Resonance Imaging Phenotypes in the Biopsy-naïve Prostate: Are They Distinct from Significant Cancer-associated Lesions? Lessons from PROMIS
False Positive Multiparametric Magnetic Resonance Imaging Phenotypes in the Biopsy-naïve Prostate: Are They Distinct from Significant Cancer-associated Lesions? Lessons from PROMIS Open
View article: Histopathological features of prostate cancer conspicuity on multiparametric MRI: protocol for a systematic review and meta-analysis
Histopathological features of prostate cancer conspicuity on multiparametric MRI: protocol for a systematic review and meta-analysis Open
Introduction Multiparametric MRI (mpMRI) has improved risk stratification for men with suspected prostate cancer. Indeed, mpMRI-visible tumours tend to be larger and of higher pathological grade than mpMRI-invisible tumours; however, conce…
View article: Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancer
Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancer Open
PIM and PI3K/mTOR pathways are often dysregulated in prostate cancer, and may lead to decreased survival, increased metastasis and invasion. The pathways are heavily interconnected and act on a variety of common effectors that can lead to …
View article: Which prostate cancers are overlooked by mpMRI? An analysis from PROMIS
Which prostate cancers are overlooked by mpMRI? An analysis from PROMIS Open
View article: What Type of Prostate Cancer Is Systematically Overlooked by Multiparametric Magnetic Resonance Imaging? An Analysis from the PROMIS Cohort
What Type of Prostate Cancer Is Systematically Overlooked by Multiparametric Magnetic Resonance Imaging? An Analysis from the PROMIS Cohort Open
Prostate cancers that are undetected by magnetic resonance imaging (MRI) are smaller and less aggressive than those that are detected, and none of the most aggressive cancers are overlooked by MRI.
View article: MP81-19 WHICH PROSTATE CANCERS ARE OVERLOOKED BY MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING? AN ANALYSIS FROM PROMIS
MP81-19 WHICH PROSTATE CANCERS ARE OVERLOOKED BY MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING? AN ANALYSIS FROM PROMIS Open
You have accessJournal of UrologyProstate Cancer: Detection & Screening VIII (MP81)1 Apr 2020MP81-19 WHICH PROSTATE CANCERS ARE OVERLOOKED BY MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING? AN ANALYSIS FROM PROMIS Joseph Norris*, Lina Carmona …
View article: PD60-02 DISCOVERY AND VALIDATION OF A NOVEL FLUID BIOMARKER FOR THE DIAGNOSIS AND RISK STRATIFICATION OF PROSTATE CANCER
PD60-02 DISCOVERY AND VALIDATION OF A NOVEL FLUID BIOMARKER FOR THE DIAGNOSIS AND RISK STRATIFICATION OF PROSTATE CANCER Open
You have accessJournal of UrologyProstate Cancer: Markers III1 Apr 2018PD60-02 DISCOVERY AND VALIDATION OF A NOVEL FLUID BIOMARKER FOR THE DIAGNOSIS AND RISK STRATIFICATION OF PROSTATE CANCER Lina Carmona Echeverria, Thomas Johnston, Avi R…